Tailoring immunosuppressive therapy in interstitial lung diseases

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 21, Issue 1, 2004, Pages 3-9

  Agostini, Carlo ^a,b,c  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b Clinical Immunology Branch   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Immunosuppressants; Interstitial lung disease; Leflunomide; Sarcoidosis

Indexed keywords

ALKYLATING AGENT; AZATHIOPRINE; BREQUINAR; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; EVEROLIMUS; FINGOLIMOD; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MIZORIBINE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PURINE ANTAGONIST; PYRIMIDINE ANTAGONIST; RAPAMYCIN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALOPECIA; BLADDER CANCER; CARDIOTOXICITY; CHRONIC INFLAMMATION; CLINICAL TRIAL; DIFFUSE ALVEOLAR HEMORRHAGE; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG TOXICITY; DRUG USE; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INTERSTITIAL LUNG DISEASE; LEUKOPENIA; LUNG HEMORRHAGE; LUNG SARCOIDOSIS; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

ALKYLATING AGENTS; CALCINEURIN; CLINICAL TRIALS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; PATIENT CARE PLANNING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES;

EID: 2042445051     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Baughman RP, Lower EE, du Bois RM: Sarcoidosis. Lancet 2003; 361: 1111-1118.
2. Sugisaki K, Yamaguchi T, Nagai S, et al: Clinical characteristics of 195 Japanese sarcoidosis patients treated with oral corticosteroids. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 222-6.
3. Kato Y, Morimoto S, Uemura A, Hiramitsu S, Ito T, Hishida H: Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 133-7.
4. Baughman RP, Iannuzzi MC, Lower EE, et al: Use of fluticasone in acute symptomatic pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 198-204.
5. Baughman RP, Alabi FO: Nonsteroidal therapy for idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2001; 7: 309-13.
6. Baughman RP: Therapeutic options for sarcoidosis: new and old. Curr Opin Pulm Med 2002; 8: 464-9.
7. Vucinic VM: What is the future of methotrexate in sarcoidosis? A study and review. Curr Opin Pulm Med 2002; 8: 470-6.
8. Baughman RP, Lynch JP: Difficult treatment issues in sarcoidosis. J Intern Med 2003; 253: 41-5.
9. Muller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U: Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999; 14: 1117-22.
10. Lewis SJ, Ainslie GM, Bateman ED: Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 87-92.
11. Baughman RP, Winget DB, Lower EE: Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17: 60-6.
12. Baughman RP, Lower EE: Leflunomide for Chronic Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 43-49.
13. Thonhofer R, Maercker C, Popper HH: Expression of sarcoidosis related genes in lung lavage cells. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 59-65.
14. Rothkrantz-Kos S, Drent M, Vuil H, et al: Decreased redox state in red blood cells from patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 114-20.
15. Milman N, Thymann M, Graudal N, Morling N: Plasma vitamin D-binding protein (GC) factors, immunoglobulin G heavy chain (GM) allotypes and immunoglobulin kappa light chain (KMI) allotype in patients with sarcoidosis and in healthy control subjects. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 97-100.
16. Salmeri FM, Sofo V, Ando FG, et al: Imbalance of serum cytokine network in sarcoid patients: index of sarcoidosis relapse? Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 53-61.
17. Hiramatsu J, Kataoka M, Nakata Y, et al: Propionibacterium acnes DNA detected in bronchoalveolar lavage cells from patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 197-203.
18. Handa T, Nagai S, Ito I, et al: Cytotoxic T-lymphocyte antigen-4 (CTLA-4) exon I polymorphism affects lymphocyte profiles in bronchoalveolar lavage of patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 190-6.
19. Grutters JC, Sato H, Pantelidis P, et al: Analysis of IL6 and ILIA gene polymorphisms in UK and Dutch patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 20-7.
20. Ziegenhagen MW, Rothe ME, Zissel G, Muller-Quernheim J: Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 185-90.
21. Planck A, Katchar K, Eklund A, Gripenback S, Grunewald J: T-lymphocyte activity in HLA-DR17 positive patients with active and clinically recovered sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 110-7.
22. Torralba KD, Quismorio FP Jr: Sarcoid arthritis: a review of clinical features, pathology and therapy. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 95-103.
23. Mana J, Montero A, Vidal M, Marcoval J, Pujol R: Recurrent sarcoidosis: a study of 17 patients with 24 episodes of recurrence. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 212-21.
24. Kidd D, Beynon HL: The neurological complications of systemic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 85-94.
25. Bergner R, Hoffmann M, Waldherr R, Uppenkamp M: Frequency of kidney disease in chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 126-32.
26. Allen RK, Sellars RE, Sandstrom PA: A prospective study of 32 patients with neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 118-25.
27. Usui Y, Kaiser ED, See RF, Rao NA, Sharma OP: Update of ocular manifestations in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 167-75.
28. Judson MA, Baughman RP, Thompson BW, et al: Two year prognosis of sarcoidosis: the ACCESS experience. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 204-11.
29. Sharma OP: Sarcoidosis of the upper respiratory tract. Selected cases emphasizing diagnostic and therapeutic difficulties. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 227-33.
30. Sharma OP, Vucinic V, James DG: Splenectomy in sarcoidosis: indications, complications, and long-term follow-up. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 66-70.
31. Padilla ML, Schilero GJ, Teirstein AS: Donor-acquired sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 18-24.
32. Lenner R, Schilero GJ, Padilla ML, Teirstein AS: Sarcoidosis presenting in patients older than 50 years. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 143-7.
33. Hamada K, Nagai S, Shigematsu M, et al: Serum concentrations of ionized calcium reflect renal function in patients with sarcoidosis. Sarcoidosis Vase Diffuse Lung Dis 2002; 19: 71-7.
34. Moller DR: Treatment of sarcoidosis - from a basic science point of view. J Intern Med 2003; 253: 31-40.
35. Allison AC: Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology 2000; 47: 63-83.
36. Reich JM: Adverse long-term effect of corticosteroid therapy in recent-onset sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 227-34.
37. Giacomelli R, Valentini G, Salsano F, et al: Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002; 29: 731-6.
38. Schnabel A, Reuter M, Gross WL: Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998; 41: 1215-20.
39. Specks U, Fervenza FC, McDonald TJ, Hogan MC: Response of Wegener's granulomatosis ulornatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001; 44: 2836-40.
40. Fink SD, Kremer JM: Successful treatment of interstitial lung disease in systemic lupus erythematosus with methotrexate. J Rheumatol 1995, 22: 967-9.
41. Baughman RP: Methotrexate for sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1998; 15: 147-9.
42. Saravanan V, Hamilton J: Advances in the treatment of rheumatoid arthritis: old versus new therapies. Expert Opin Pharmacother 2002; 3: 845-56.
43. Emery P, Breedveld FC, Lemmel EM, et al: A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000; 39: 655-65.
44. Hunt SA: New immunosuppressive agents in clinical use: mycophenolate mofetil and tacrolimus. Cardiol Rev 2000; 8: 180-4.
45. Moder KG: Mycophenolate mofetil: new applications for this immunosuppressant. Ann Allergy Asthma Immunol 2003; 90: 15-19; quiz 20, 78.
46. Adu D, Cross J, Jayne DR: Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus 2001; 10: 203-8.
47. Assmann T, Ruzicka T: New immunosuppressive drugs in dermatology (mycophenolate mofetil, tacrolimus): unapproved uses, dosages, or indications. Clin Dermatol 2002; 20: 505-14.
48. Ford AC, Towler RJ, Moayyedi P, Chalmers DM, Axon AT: Mycophenolate mofetil in refractory inflammatory bowel disease. Aliment Pharmacol Ther 2003; 17: 1365-69.
49. Samad AS, Lindsley CB: Treatment of pulmonary hemorrhage in childhood systemic lupus erythematosus with mycophenolate mofetil. South Med J 2003; 96: 705-7.
50. Smak Gregoor PJ, van Gelder T, Weimar W: Mycophenolate mofetil, Cellcept, a new immunosuppressive drug with great potential in internal medicine. Neth J Med 2000; 57: 233-46.
51. Treiber G: Mycophenolate mofetil for therapy-resistant interstitial lung disease associated with ulcerative colitis. Am J Gastroenterol 2000; 95: 3674-5.
52. Stratton RJ, Wilson H, Black CM: Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology 2001; 40: 84-8.
53. Altschuler EL: Consideration of mycophenolate mofetil for idiopathic pulmonary fibrosis. Med Hypotheses 2001; 57: 701-2.
54. Kuypers DR, Vanrenterghem YC: Tailoring immunosuppressive therapy. Nephrol Dial Transplant 2002; 17: 2051-4.
55. Moolman JA, Bardin PG, Rossouw DJ, Joubert JR: Cyclosporin as a treatment for interstitial lung disease of unknown aetiology. Thorax 1991; 46: 592-5.
56. Puttick MP, Klinkhoff AV. Chalmers A, Ostrow DN: Treatment of progressive rheumatoid interstitial lung disease with cyclosporine. J Rheumatol 1995; 22: 2163-65.
57. Ogawa D, Hashimoto H, Wada J, et al: Successful use of cyclosporin A for the treatment of acute interstitial pneumonitis associated with rheumatoid arthritis. Rheumatology 2000; 39: 1422-4.
58. Chang HK, Park W, Ryu DS: Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report. J Korean Med Sci 2002; 17: 270-3.
59. Tanaka F, Origuchi T, Migita K, et al: Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis demnatomyositis. Intern Med 2000; 39: 428-30.
60. Miyake S, Ohtani Y, Sawada M, et al: Usefulness of cyclosporine A on rapidly progressive interstitial pneumonia in demnatomyositis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 128-33.
61. Kobayashi I, Yamada M, Takahashi Y, et al: Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A. Rheumatology (Oxford) 2003; 42: 371-4.
62. Morton RL, Shoemaker LR, Eid NS: Steroid-refractory neonatal eosinophilic pneumonia responsive to cyclosporin A. Am J Respir Crit Care Med 1999; 160: 1019-22.
63. Sugisaki K, Takeda I, Iwadate H, Kanno T, Nishimaki T, Kasukawa R: Prevention of progression of interstitial lung lesions by early combination therapy with corticosteroids and cyclosporine/cyclophosphamide in two patients with amyopathic dermatomyositis. Fukushima J Med Sci 2002; 48: 103-10.
64. Wyser CP, van Schalkwyk EM, Alheit B, Bardin PG, Joubert JR: Treatment of progressive pulmonary sarcoidosis with cyclosporin A. A randomized controlled trial. Am J Respir Crit Care Med 1997; 156: 1371-6.
65. Oddis CV: Current approach to the treatment of polymyositis and dermatomyositis. Curr Opin Rheumatol 2000: 12: 492-7.
66. Koga T, Yano T, Ichikawa Y, Oizumi K, Mochizuki M: Pulmonary infiltrates recovered by FK506 in a patient with Behcet's disease. Chest 1993; 104: 309-11.
67. Henry MT, Newstead CG: Sirolimus: another cause of drug-induced interstitial pneumonitis. Transplantation 2001; 72: 773-4.
68. Singer SJ, Tiernan R, Sullivan EJ: Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients. N Engl J Med 2000; 343: 1815-6.
69. Agostini C: Cytokine and chemokine blockade as immunointervention strategy for the treatment of diffuse lung diseases. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 18-22.
70. Yee AM, Pochapin MB: Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med 2001; 135: 27-31.
71. Baughman RP, Lower EE: Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 70-4.
72. Cook MC: Infliximab therapy for complicated sarcoidosis. Ann Intern Med 2002; 137: 296-7; author reply 296-7.
73. Khanna D, Liebling MR, Louie JS: Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 2003; 30: 1864-7.
74. Utz JP, Limper AH, Kalra S, et al: Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124: 177-85.
75. Hellmich B, Gross WL: Recent progress in the pharmacotherapy of Churg-Strauss syndrome. Expert Opin Pharmacother 2004; 5: 25-35.
76. Arbach O, Gross WL, Gause A: Treatment of refractory Churg-Strauss-Syndrome (CSS) by TNF-alpha blockade. Immunobiology 2002; 206: 496-501.
77. Sfikakis PP, Behcet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 2002; 61 Suppl 2: ii51-53.
78. Tutuncu Z, Morgan GJ Jr, Kavanaugh A: Anti-TNF therapy for other inflammatory conditions. Clin Exp Rheumatol 2002; 20: S146-51.
79. Lamprecht P, Voswinkel J, Lilienthal T, et al: Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002; 41: 1303-7.
80. Booth AD, Jefferson HJ, Ayliffe W, Andrews PA, Jayne DR: Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann Rheum Dis 2002 61: 559.
81. Raghu G, Brown KK, Bradford WZ, et al: A placebo-controlled trial of interferon gamma-lb in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350: 125-33.
82. Kahan BD, Karlix JL, Ferguson RM, et al: Pharmacodynamics, pharmacokinetics and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Transplantation 2003; 76: 1079-84.
83. Bohler T, Waiser J, Schutz M, Schumann B, Neumayer HH, Budde K: Pharmacodynamics of FTY720, the first member of a new class of immune-modulating therapeutics in transplantation medicine. Int J Clin Pharmacol Ther 2003; 41: 482-7.